BioSpace News Archive

Riverain Technologies, the pioneer of Clear Visual Intelligence™ for chest imaging interpretation, was selected by the Veterans Health Administration to provide its unique imaging interpretation solution, ClearRead™ CT, to the Veteran Affair’s Lung Precision Oncology Program.

Pharmaceutics International, Inc., a contract development and manufacturing organization has been promoted Devan Patel to Vice President – Client Services, where he will oversee Pii’s Business Operations & Program Management functions.

The Board of Directors of IronMatt, The Matthew Larson Foundation for Pediatric Brain Tumors, is pleased to have been acknowledged in a recent issue of Cancer Discovery for their support of influential immunotherapy research in the lab and in a clinical trial.

QuVa Pharma, Inc. announced that is has developed a two-sided single label for its product portfolio of compounded IV bags.

Today, the U.S. Food and Drug Administration issued a Federal Register notice, Safety and Effectiveness of Certain Naloxone Hydrochloride Drug Products for Nonprescription Use, that may help facilitate the development and approval of certain nonprescription naloxone drug products, including through the switch of certain naloxone drug products from prescription status to nonprescription status.

As a cutting-edge rehabilitation solution provider, after first appearing at MEDICA 2021, Siyi Intelligence once again presented its SYREBO® soft robotic hand rehabilitation gloves and launched the new generation HRC12 robotic rehab glove for home use at MEDICA 2022 (Hall 4-Stand B47).

The global genomics in cancer care market is forecasted to grow at a rate of 16.3% from USD 11.89 billion in 2019 to USD 39.94 billion in 2030.

The global downstream processing market is forecasted to grow at a rate of 12.7%, from USD 18.22 billion in 2019 to USD 45.49 billion in 2030.

The global spatial genomics & transcriptomics market size was USD 178.4 Million in 2020 and is expected to register a CAGR of 18.1% during the forecast period.

Sebela Pharmaceuticals® announced a new division of the company named Sebela Women’s Health along with the appointment of Kelly Culwell, MD, as Head of Research and Development for the division.